Merrill Lynch maintains Angiotech neutral rating

Angiotech Pharmaceuticals, Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating as the company prepares to report third-quarter earnings this week. Merrill Lynch estimates revenues of $49 million, including $45 million in Taxus stent royalties. Merrill Lynch will review the company's outlook pending details on the Taxus Liberte launch in the European Union and the United States, the outcome of patent litigation in the U.K., Netherlands and Australia, among other factors. Shares of the Vancouver, B.C.-based specialty pharmaceutical company were up $0.15, or 1.13%, at $13.40 on volume of 430,593 shares versus the three-month running average of 521,520 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.